The global cancer biologics market should reach $143.0 billion by 2026 from $77.5 billion in 2021 at a compound annual growth rate (CAGR) of 13.0% for the forecast period of 2021 to 2026.
The monoclonal antibodies segment of the global cancer biologics market is expected to grow from $68.0 billion in 2021 to $124.1 billion in 2026 at a CAGR of 12.8% for the forecast period of 2021 to 2026.
The CAR T-cell therapy segment of the global cancer biologics market is expected to grow from $1.5 billion in 2021 to $7.3 billion in 2026 at a CAGR of 37.5% for the forecast period of 2021 to 2026.
Report Scope
This report provides an update on BIO048C Biological Therapies for Cancer: Technologies and Global Markets. It reviews global markets for biologic therapeutics for cancer and forecasts trends for the use of biologics and cancer treatments through 2026. It discusses important biologics, market share by cancer type, products on the market, market share by company and statistical information for cancer types prevalent globally. It also includes current issues and trends affecting the industry, as well as factors influencing demand. The report covers biological products in development, biological products in clinical trials, and currently marketed and late-stage development biologic cancer products.
The market and sales data for recent years give strong support for research and development (R&D) programs and the move toward biologic treatment for cancer, as well as within biologics toward human monoclonal antibodies, vaccines and CAR T-cell therapies.
The biologic drug classes discussed in this report with a special focus on cancer treatment are:
- Monoclonal antibodies
- Vaccines.
- CAR T-cell therapies.
The following approaches to cancer therapeutics are excluded in the report:
- Chemotherapy.
- Alkylating agents.
- Antimetabolites.
- Cytotoxic agents.
- Plant derivatives and hormone therapy corticosteroids.
- Hormone antagonists/antagonists aromatase inhibitors.
- Radiation therapy.
- Adjunctive and Supportive therapy.
- Interferons and Interleukins.
- Other immunostimulants.
- Biological therapies for the treatment of other diseases will not be addressed in this report.
The report also covers biological products in development, biological products in clinical trials, and currently marketed and late-stage development biologic cancer products, including:
- Treatment trends and sales patterns across major cancer indications for U.S., Europe (France, Germany, Italy, Spain, the U.K.), Asia-Pacific (Japan, China, India, and Australia) and the rest of the world.
- Market performance of major pharmaceutical companies.
- Sales of leading cancer products across major indications from 2018 to 2020.
- Biosimilars and their impact on currently marketed cancer biotherapeutics.
- Competitor landscape and share analysis.
This updated report includes the following new information:
- The latest version of the report provides elaborated information of the cancer biologics market at a regional level. The current report provides regional and country-level market segmentation for the U.S., Europe (France, Germany, Italy, Spain, the U.K.), Asia-Pacific (Japan, China, India, and Australia) and the rest of the world.
- The latest version of the report provides elaborated information of competitor landscape and company share analysis.
- The latest version of the report also provides elaborated information on the novel CAR T-cell therapies.
The Report Includes
- 29 data tables and 80 additional tables
- An updated review of the global markets of biological therapies for cancer treatment and related technologies
- Analyses of the global market trends, with data from 2020, estimates for 2021-2025, and projections of compound annual growth rates (CAGRs) through 2026
- Estimation of the market size and revenue forecast for cancer biologics market and its sub-segments, and corresponding market share analysis by product type, cancer type, and geographic region
- Coverage of biological products in development, biological products in clinical trials, and currently marketed and late-stage development biologic cancer products
- Discussion of biological therapies products available in the market, industry structure, cancer markets in newly emerging therapeutics, and analysis of biosimilars drugs and their impact on the market
- Review of cancer statistics and epidemiology insights and SWOT analysis of various cancer biotherapeutics present in the market
- A look at major issues and trends with relate to the R&D of more effective cancer treatment, and new cancer therapeutics in development, and outlook on cancer clinical trials
- Key marketed drugs and recent approvals, sales statistics and past performance of the top selling biologics, and insight into their patent expiries
- Insight into the growth development strategies of the key market players operating within the global market; their key competitive landscape and company share analysis
- Descriptive company profiles of the leading market participants, including Amgen Inc., Eli Lilly and Co., GlaxoSmithKline, Merck & Co. Inc., and Pfizer Inc.
Table of Contents
Chapter 1 Introduction
- Study Goals and Objectives
- Reasons for Doing This Study
- What's New in This Update
- Scope of Report
- Information Sources
- Methodology
- Geographic Breakdown
- Analyst's Credentials
- Custom Research
- Related Reports
Chapter 2 Summary and Highlights
Chapter 3 Clinical Overview
- Definition of Cancer
- Risk Factors for and Causes of Cancer
- Tobacco Use
- Alcohol Abuse and Cancer Statistics
- Obesity and Cancer Statistics
- Infectious Diseases and Cancer
- Inherited Genes: Diseases and Cancer
- Sun, Ultraviolet Radiation and Cancer
- Hormones and Cancer
- Overview of Common Cancer Treatments
- Surgery
- Chemotherapy
- Radiation Therapy
- Hormone Therapy
- Targeted Therapy and Immunotherapy
- Overview of Cancer Burden and Related Costs
Chapter 4 Cancer Types
- Lung Cancer
- Overview
- Non-small-Cell Lung Cancer (NSCLC)
- Small-Cell Lung Cancer (SCLC)
- Other Lung Cancers
- Treatments
- Bladder Cancer
- Overview
- Treatments
- Breast Cancer
- Overview
- Common Breast Cancer Mutations
- Treatments
- Cervical Cancer
- Overview
- Treatments
- Colorectal Cancer
- Overview
- Treatments
- Kidney Cancer
- Treatments
- Leukemia
- Overview
- Treatment
- Lymphoma
- Overview
- Treatment
- Multiple Myeloma
- Overview
- Treatments
- Liver Cancer
- Overview
- Treatments
- Melanoma
- Overview
- Treatments
- Brain Cancer
- Overview
- Treatments
- Ovarian Cancer
- Treatments
- Prostate Cancer
- Treatments
- Stomach Cancer
Chapter 5 Cancer Epidemiology
- Epidemiology by Cancer Type/Site
- Global Cancer Incidence
- Global Cancer Prevalence, 2020
- Global Cancer Mortality Overview
- Cancer Epidemiology by Region
- Europe
- North America
- Asia-Pacific
- Rest of the World
Chapter 6 Key Marketed Products
- Current Drugs and Recent Approvals
- Monoclonal Antibodies
- Vaccines
- CAR T-Cell Therapies
- Sales Statistics of Selected Key Biologics
Chapter 7 Cancer Clinical Trials and Pipeline Biologics
- Overview of Cancer Clinical Trials
- Key Pipeline Drugs by Company
- Key Pipeline Drug Profiles
- Penpulimab
Chapter 8 Impact of COVID-19 Pandemic on the Market for Cancer Biologics
- Overview
- Current Outlook
- Impact of COVID-19 on Cancer Care
- Delay in Elective Surgical Procedures
- Trade Restrictions and Supply Disruptions
Chapter 9 Market Breakdown by Product and Technology
- Monoclonal Antibodies
- Market Overview
- Market Size and Forecast
- Market Segmentation by Geography
- CAR T-Cell Therapy
- Market Overview
- Market Size and Forecast Analysis
- Market Segmentation by Geography
- Cancer Vaccines
- Market Overview
- Market Size and Forecast Analysis
- Market Segmentation by Geography
Chapter 10 Market Breakdown by Region
- Global Market Overview
- North America
- United States
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Asia-Pacific
- Japan
- China
- India
- Australia
- Rest of the World
Chapter 11 Cancer Biologics Market Outlook: Issues and Trends
- Medicare Coverage and Reimbursement for Cancer Care
- Pricing Strategies for Cancer Biologics
- Cancer Drug Costs
- Personalized Medicine
- Overview of Biosimilars
- Biosimilars and Costs of Cancer Drugs
- Biosimilars in India and China
- Hurdles For Biosimilars
- Biosimilars in Europe
- Issues with Biosimilars
- Data Exclusivity Periods
- Differences Between Biopharmaceuticals and Biogenerics
- Biosimilars and Patient Safety
Chapter 12 Competitive Landscape
- Competitive Overview
- Competitive Share Analysis
- Key Merger and Acquisitions in the Global Cancer Market
- Key Licensing Deals in Global Cancer Market
Chapter 13 Company Profiles
- Amgen Inc.
- AstraZeneca
- Bristol Myers Squibb
- Eli Lilly And Co.
- Genmab
- Gilead Sciences Inc.
- Glaxosmithkline
- Janssen Pharmaceuticals Inc.
- Merck & Co.
- Novartis
- Pfizer Inc.
- Roche (F. Hoffmann-La Roche Ag)
Chapter 14 Appendix: Acronyms
List of Tables
Summary Table A: Global Market for Cancer Biologics, by Product Type, Through 2026
Summary Table B: Global Market for Cancer Biologics, by Region, Through 2026
Table 1: Global High BMI-Related Cancer Deaths and DALYs, 2017
Table 2: National Expenditure Estimates for Cancer Care, by Cancer Type, 2015 vs. 2020
Table 3: NSCLC Treatments
Table 4: SCLC Treatments
Table 5: Bladder Cancer Treatments
Table 6: Breast Cancer Treatments
Table 7: Cervical Cancer Treatments
Table 8: Colorectal Cancer Treatments
Table 9: Kidney Cancer Treatments
Table 10: Leukemia Treatments
Table 11: NHL Treatments
Table 12: Multiple Myeloma Treatments
Table 13: Liver Cancer Treatments
Table 14: Melanoma Treatments
Table 15: Brain Cancer Treatments
Table 16: Ovarian Cancer Treatments
Table 17: Prostate Cancer Treatments
Table 18: Stomach Cancer Treatments
Table 19: Global Cancer Incidence, by Cancer Type/Site, 2020
Table 20: Global Cancer Mortality, by Cancer Type/Site, 2020
Table 21: Estimated Number of New Cancer Cases in the U.S., by Cancer Type/Site and Sex, 2021
Table 22: Estimated Number of Cancer Deaths in the U.S., by Cancer Type/Site and Sex, 2021
Table 23: Comprehensive List of FDA-Approved Monoclonal Antibodies
Table 24: Rituxan (Rituximab) Drug Profile
Table 25: Avastin Drug Profile
Table 26: Herceptin Drug Profile
Table 27: Erbitux Drug Profile
Table 28: Erbitux Approvals, by Year
Table 29: Opdivo Drug Profile
Table 30: Opdivo: Recent FDA Approvals and Regulatory Updates
Table 31: Keytruda: Recent FDA Approvals and Regulatory Updates
Table 32: Darzalex Drug Profile
Table 33: Darzalex: FDA Approvals and Regulatory Updates
Table 34: Perjeta Drug Profile
Table 35: Imfinzi Drug Profile
Table 36: Tecentiq Drug Profile
Table 37: Tecentriq: FDA Approvals and Regulatory Updates
Table 38: Xgeva Drug Profile
Table 39: Kadcyla Drug Profile
Table 40: Yervoy Drug Profile
Table 41: Yervoy: Recent FDA Approvals and Regulatory Updates
Table 42: Trodelvy Drug Profile
Table 43: Blenrep Drug Profile
Table 44: Jemperli Drug Profile
Table 45: Zynlonta Drug Profile
Table 46: Rybrevant Drug Profile
Table 47: Sarclisa Drug Profile
Table 48: Phesgo Drug Profile
Table 49: Monjuvi Drug Profile
Table 50: Provenge Drug Profile
Table 51: Provenge: Key Product Highlights
Table 52: Gardasil/Gardasil 9 Drug Profile
Table 53: Gardasil/Gardasil 9: FDA-Approved Cancer Indications by Sex
Table 54: Sales Statistics of Key Cancer Biologics, by Leading Manufacturers, 2018-2020
Table 55: Number of Clinical Trials, by Cancer Type/Site and Phase, 2021
Table 56: List of Selected Key Pipeline Cancer Biologics
Table 57: Penpulimab Drug Profile
Table 58: Sintilimab (Tyvyt) Drug Profile
Table 59: Toripalimab Drug Profile
Table 60: Tisotumab Vedotin Drug Profile
Table 61: Retifanlimab Drug Profile
Table 62: Glofitamab Drug Profile
Table 63: Tiragolumab Drug Profile
Table 64: Mosunetuzumab Drug Profile
Table 65: Canakinumab Drug Profile
Table 66: Datopotamab Deruxtecan Drug Profile
Table 67: Reported COVID-19 Cases and Deaths, by Country, May 2021
Table 68: Global Market for Cancer Biologics, by Product Type, Through 2026
Table 69: List of Key Target Sites for Monoclonal Antibodies
Table 70: Global Market for Monoclonal Antibodies to Treat Cancer, by Region, Through 2026
Table 71: Global Market for CAR T-Cell Therapy for Cancer, by Region, Through 2026
Table 72: Global Market for Cancer Vaccines, by Region, Through 2026
Table 73: Global Market for Cancer Biologics, by Region, Through 2026
Table 74: North American Market for Cancer Biologics, by Product Type, Through 2026
Table 75: Key FDA Approved Novel Biologics, 2020 and 2021
Table 76: Canada: Cancer Incidence, Mortality and Survival Estimates, by Cancer Type/Site, 2020
Table 77: Key EMA Approved Novel Biologics, 2020 and 2021
Table 78: European Market for Cancer Biologics, by Product Type, Through 2026
Table 79: U.K.: Cancer Incidence and Mortality, by Cancer Type/Site, 2020
Table 80: Germany: Cancer Incidence and Mortality, by Cancer Type/Site, 2020
Table 81: France: Cancer Incidence and Mortality, by Cancer Type/Site, 2020
Table 82: Italy: Cancer Incidence and Mortality, by Cancer Type/Site, 2020
Table 83: Spain: Cancer Incidence and Mortality, by Cancer Type/Site, 2020
Table 84: Asia-Pacific Market for Cancer Biologics, by Product Type, Through 2026
Table 85: Japan: Cancer Incidence, Mortality and Survival Estimates, by Cancer Type/Site, 2020
Table 86: Key Approved Novel Cancer Biologics by Japanese MHLW, 2020-2021
Table 87: China: Cancer Incidence and Mortality, by Cancer Type/Site, 2020
Table 88: Key Approved Novel Cancer Biologics by Chinese NMPA, 2019 and 2020
Table 89: India: Cancer Incidence and Mortality, by Cancer Type/Site, 2020
Table 90: Australia: Cancer Incidence, Mortality and Survival Estimates, by Cancer Type/Site, 2020
Table 91: Rest of the World Market for Cancer Biologics, by Product Type, Through 2026
Table 92: Key Federal Health Insurance Programs in the U.S.
Table 93: Top Mergers and Acquisitions in the Global Cancer Therapeutics Market, 2019-2020
Table 94: Top Licensing Deals of Cancer Drugs, 2019-2020
Table 95: Amgen: Key Cancer Biologics Product Portfolio
Table 96: AstraZeneca: Key Cancer Biologics Product Portfolio
Table 97: Bristol Myers Squibb: Key Cancer Biologics Product Portfolio
Table 98: Eli Lilly and Co.: Key Cancer Biologics Product Portfolio
Table 99: Genmab: Key Cancer Biologics Product Portfolio
Table 100: Gilead Sciences: Key Cancer Biologics Product Portfolio
Table 101: GlaxoSmithKline: Key Cancer Biologics Product Portfolio
Table 102: Janssen Pharmaceuticals: Key Cancer Biologics Product Portfolio
Table 103: Merck& Co.: Key Cancer Biologics Product Portfolio
Table 104: Novartis: Key Cancer Biologics Product Portfolio
Table 105: Pfizer Inc.: Key Cancer Biologics Product Portfolio
Table 106: Roche: Key Cancer Biologics Product Portfolio
Table 107: Acronyms Used in This Report
List of Figures
Summary Figure A: Global Market Shares of Cancer Biologics, by Product Type, 2020
Summary Figure B: Global Market Shares of Cancer Biologics, by Region, 2020
Figure 1: Global Tobacco Consumption Population, by Sex and Country, 2019
Figure 2: Global Incidence of Alcohol-Attributable Cancers, by Cancer Type and Sex
Figure 3: Share of Diagnosed Population of Infections-Attributable to Cancers, by Type, 2018
Figure 4: Cancers Attributable to UV Radiation Exposure, by Region and Age Group, 2012
Figure 5: Productivity Losses Due to Cancer Attributed to Premature Deaths in Emerging Economies, 2017
Figure 6: U.S. National Cancer Costs, Projections and Trends, 2015-2030
Figure 7: Global Cancer Incidence, by Sex and Cancer Type/Site, 2020
Figure 8: Global Cancer Incidence, by Region, 2020
Figure 9: Global Cancer Incidence Trends, by Cancer Type/Site, 2020-2030
Figure 10: Global Cancer Prevalence by Cancer Type/Site and Sex, 2020
Figure 11: Avastin: Global Product Revenue, 2018-2020
Figure 12: Herceptin: Global Product Revenue, 2018-2020
Figure 13: Erbutix: Global Product Revenue, 2019 and 2020
Figure 14: Opdivo: Global Product Revenue, 2018-2020
Figure 15: Keytruda: Global Product Revenue, 2018-2020
Figure 16: Darzalex: Global Product Revenue, 2018-2020
Figure 17: Perjeta: Global Product Revenue, 2018-2020
Figure 18: Imfinzi: Global Product Revenue, 2018-2020
Figure 19: Tecentriq: Global Product Revenue, 2018-2020
Figure 20: Xgeva: Global Product Revenue, 2018-2020
Figure 21: Kadcyla: Global Product Revenue, 2018-2020
Figure 22: Yervoy: Global Product Revenue, 2018-2020
Figure 23: Gardasil and Cervarix: Comparative Global Sales Trend, 2010-2020
Figure 24: Heplisav-B: Global Net Product Revenue, 2018-2020
Figure 25: Global Market Shares of Cancer Biologics, by Product Type, 2020
Figure 26: Global Market for Cancer Monoclonal Antibodies, 2020-2026
Figure 27: Number of Approved Cancer Monoclonal Antibodies, by Year, 2010-2020
Figure 28: Comparison of Approved Indications for Matrix to CAR T-Cell Therapies
Figure 29: Global Market for CAR T-Cell Therapies, 2020-2026
Figure 30: Product Revenue of Key CAR T-Cell Therapy (Yescarta), by Region, 2018-2020
Figure 31: Global Market for Cancer Vaccines, 2020-2026
Figure 32: Global Market for Cancer Biologics, by Region, 2020-2026
Figure 33: North American Market Shares of Cancer Biologics, by Product Type, 2020
Figure 34: U.S. Market for Cancer Biologics, 2020-2026
Figure 35: U.S. Leading Sites of New Cancer Incidence and Deaths, 2021
Figure 36: Canadian Market for Cancer Biologics, 2020-2026
Figure 37: European Market Shares of Cancer Biologics, by Product Type, 2020
Figure 38: U.K. Market for Cancer Biologics, 2020-2026
Figure 39: German Market for Cancer Biologics, 2020-2026
Figure 40: French Market for Cancer Biologics, 2020-2026
Figure 41: Italian Market for Cancer Biologics, 2020-2026
Figure 42: Spanish Market for Cancer Biologics, 2020-2026
Figure 43: Asia-Pacific Market Shares of Cancer Biologics, by Product Type, 2020
Figure 44: Japanese Market for Cancer Biologics, 2020-2026
Figure 45: Chinese Market for Cancer Biologics, 2020-2026
Figure 46: Indian Market for Cancer Biologics, 2020-2026
Figure 47: Australian Market for Cancer Biologics, 2020-2026
Figure 48: Distribution of Cancer Care Spending in the U.S., by Treatment Cost, 2018
Figure 49: Illustration of Traditional vs. PPM Based Model for Cancer Treatment
Figure 50: Global Market Shares of Cancer Biologics, by Manufacturer, 2020
Figure 51: Amgen: Annual Revenue, 2016-2020
Figure 52: AstraZeneca: Annual Revenue, 2016-2020
Figure 53: Bristol Myers Squibb: Annual Revenue, 2016-2020
Figure 54: Bristol Myers Squibb: Revenue Share, by Geography, 2016-2020
Figure 55: Eli Lilly and Co.: Annual Revenue, 2016-2020
Figure 56: Eli Lilly and Co.: Revenue Share, by Therapy Area, 2020
Figure 57: Genmab: Annual Revenue, 2016-2020
Figure 58: Gilead Sciences: Annual Revenue, 2016-2020
Figure 59: GlaxoSmithKline: Annual Revenue, 2016-2020
Figure 60: GlaxoSmithKline: Revenue Share, by Business Segment, 2020
Figure 61: Johnson & Johnson: Annual Revenue, 2016-2020
Figure 62: Johnson & Johnson: Revenue Share, by Segment, 2020
Figure 63: Merck & Co.: Annual Revenue, 2016-2020
Figure 64: Novartis: Annual Revenue, 2016-2020
Figure 65: Pfizer Inc.: Annual Revenue, 2016-2020
Figure 66: Pfizer Inc.: Annual Revenue Share, by Geography, 2018-2020
Figure 67: Roche: Annual Revenue, 2016-2020
Figure 68: Roche: Revenue Share, by Therapy Area (Pharma Division), 2020
Samples
LOADING...
Executive Summary
Growth factors include the approval and launch of novel first-in-class cancer biologics, increasing research and commercial collaborations, expansion of indications for existing therapies, increasing cancer incidence and prevalence pool, increasing emergence of technologically advanced drug discovering and manufacturing technologies, and improved cancer prevention strategies worldwide.
Reasons for Doing This Study
A rise in the number of cancer diagnoses, along with wider access and affordability of treatment regimes in developing countries, will stimulate growth in the global cancer therapy market. Cancer is the second leading cause of death in the U.S., and according to the American Cancer Society (ACS), 50% of men and 30% of women will develop some form of cancer in their lifetimes. In 2020, 19.3 million new cancer cases were diagnosed and about 10 million people died due to cancer. The incidence of cancers is anticipated to surpass 24 million in 2030 and 30 million in 2040.
Newer biotherapeutics have emerged in the past few years that have had significant impacts on cancer treatment and healthcare. The demand for newer and innovative oncology drugs will continue to grow as global healthcare systems emphasize cancer detection and treatment.
Companies Mentioned
- Amgen Inc.
- AstraZeneca
- Bristol Myers Squibb
- Eli Lilly And Co.
- Genmab
- Gilead Sciences Inc.
- Glaxosmithkline
- Janssen Pharmaceuticals Inc.
- Merck & Co.
- Novartis
- Pfizer Inc.
- Roche (F. Hoffmann-La Roche Ag)
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 258 |
| Published | September 2021 |
| Forecast Period | 2021 - 2026 |
| Estimated Market Value ( USD | $ 22.4 Billion |
| Forecasted Market Value ( USD | $ 34.7 Billion |
| Compound Annual Growth Rate | 9.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
